Korean J Gynecol Oncol.  2005 Jun;16(2):104-112.

Expression of Matrix Metalloproteinase and Urokinase-type Plasminogen Activator in Epithelial Tumors of the Ovary

Affiliations
  • 1Department of Obstetrics and Gynecology, Kyungpook National University School of Medicine, Daegu, Korea. parkis@knu.ac.kr

Abstract


OBJECTIVE
The most important biologic characters of malignant tumor are invasion and metastasis, and extracellular matrix is first barrier in metastatic process. Therefore, proteases are linked to the malignant phenotype of different solid tumor.
METHODS
In this study, the expression of the matrix metalloproteinase (MMP)-2 and MMP-9 and of the serine protease urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1 (PAI-1) in the ovarian epithelial tumors was investigated. Immunohistochemical expression of MMP-2, MMP-9, uPA, and PAI-1 were analyzed in formalin fixed tumor tissues of 20 benign cystadenomas, 20 low malignant potential (LMP) tumors, and 20 malignant ovarian cancer, including 10 FIGO stage I cancer and 10 stage III cancer. In the same tissue extracts, DNA levels of MMP-2, MMP-9, uPA, and PAI-1 were determined by PCR.
RESULTS
The immunohistochemical expression and DNA level of MMP-2, MMP-9, uPA, and PAI-1 were low in benign ovarian tumors but significantly increased LMP tumors and malignant ovarian cancers. The highest values of all of the proteolytic enzymes were detected in stage III ovarian cancers with omentum metastases. There are significant correlations between expression of uPA and MMP.
CONCLUSION
These results suggest that high expression of MMP-2, MMP-9, and uPA is associated with activity of tumor invasion and metastasis, and expressions of MMP-2 and MMP-9 are correlated with uPA activity.

Keyword

MMP-2; MMP-9; Urokinase-type plasminogen activator; Plasminogen activator inhibitor-1; Ovarian tumor

MeSH Terms

Cystadenoma
DNA
Extracellular Matrix
Female
Formaldehyde
Neoplasm Metastasis
Omentum
Ovarian Neoplasms
Ovary*
Peptide Hydrolases
Phenotype
Plasminogen Activator Inhibitor 1
Plasminogen Activators
Polymerase Chain Reaction
Serine Proteases
Tissue Extracts
Urokinase-Type Plasminogen Activator*
DNA
Formaldehyde
Peptide Hydrolases
Plasminogen Activator Inhibitor 1
Plasminogen Activators
Serine Proteases
Tissue Extracts
Urokinase-Type Plasminogen Activator
Full Text Links
  • KJGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr